[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616733":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"NMIBC Participants: Routine Clinical Practice Setting",null,"Participants with confirmed diagnosis of NMIBC and who have initiated first dose of TAR-200 in a real-world clinical setting, within 6 weeks prior to baseline visit\u002FStudy visit 1 will be observed for 24 months from the initiation of the first dose of TAR-200, or until the participant dies, is lost to follow-up, or withdraws consent in the study. No intervention will be administered as a part of this study.",[13],{"name":14,"affiliation":5,"role":15},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":10},"Eliza M. Raymundo, MD, DMCC, FPUA, FPCS","1-669-800-7705",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"Arkansas Urology","RECRUITING","Little Rock","Arkansas","72211","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-92.28959,34.74648,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100616733","a-study-to-assess-real-world-use-and-outcomes-of-tar-200-for-participants-with-non-muscle-invasive-bladder-cancer-nmibc-in-the-united-states-100616733",false,"NCT07309445","A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States","A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US","Nova-sTAR","Inclusion criteria:\n\n* Has a confirmed diagnosis of NMIBC based on TURBT or cold cup biopsy\n* Initiated first dose of TAR-200 in a real-world setting within 6 weeks prior to baseline visit\u002FStudy visit 1\n* Participants with childbearing potential are required to adhere to contraceptive recommendations as specified in the approved product labeling for TAR-200. Additionally, participants should seek consultation with their physician for personalized contraceptive advice\n* Must provide informed consent as described in the protocol\n\nExclusion criteria:\n\n* Has any medical condition deemed by the health care practitioner (HCP) as contraindicated to receive TAR-200 treatment\n* Had previous treatment with TAR-200 discontinued prior to baseline visit\u002FStudy visit 1\n* Previously received TAR-200 intravesically as part of a clinical trial(s)\n* Previously received greater than (\\>) 2 doses\u002Fcycles of TAR-200 in the real-world setting\n* Currently participating in an interventional bladder cancer clinical trial","ALL","18 Years",{"count":53,"type":54},150,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).",[58],"Non-Muscle Invasive Bladder Neoplasms","2026-06-04",{"date":61,"type":62},"2026-06-05","ACTUAL",{"date":64,"type":54},"2026-06-30",{"date":66,"type":54},"2029-10-09",{"name":5,"class":6},1]